ReviewHandbook of clinical neurology2021
The promiscuity of the oxytocin-vasopressin systems and their involvement in autism spectrum disorder.
Review in Handbook of clinical neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 19 citations in OpenAlex.
- Arginine-vasopressin systems in autistic phenotype schizophrenia: effect of a genetic variant of AVPR1a and AVPR1b.Journal of neural transmission (Vienna, Austria : 1996) · 2026Article
- Circuit logic of oxytocin and vasopressin complementary actions.Frontiers in neuroscience · 2026Review
- Deciphering autism heterogeneity: a molecular stratification approach in four mouse models.Translational psychiatry · 2024Article
- Transcriptome analysis identifies an ASD-Like phenotype in oligodendrocytes and microglia from C58/J amygdala that is dependent on sex and sociability.Behavioral and brain functions : BBF · 2024Article
- Peripheral oxytocin levels are linked to hypothalamic gray matter volume in autistic adults: a cross-sectional secondary data analysis.Scientific reports · 2024Article
- A journey from speech to dance through the field of oxytocin.Comprehensive psychoneuroendocrinology · 2023Review
- Vasopressin as Possible Treatment Option in Autism Spectrum Disorder.Biomedicines · 2023Review
- Oxytocin receptors in the Magel2 mouse model of autism: Specific region, age, sex and oxytocin treatment effects.Frontiers in neuroscience · 2023Article
- Can Translational Social Neuroscience Research Offer Insights to Mitigate Structural Racism in the United States?Biological psychiatry. Cognitive neuroscience and neuroimaging · 2022Review
- Rethinking the Architecture of Attachment: New Insights into the Role for Oxytocin Signaling.Affective science · 2022Review
- Sex-specific and social experience-dependent oxytocin-endocannabinoid interactions in the nucleus accumbens: implications for social behaviour.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
Oxytocin and vasopressin systems have been studied separately in autism spectrum disorder (ASD). Here, we provide evidence from an evolutionary and neuroscience perspective about the shared mechanisms and the common roles in regulating social behaviors. We first discuss findings on the evolutionary history of oxytocin and vasopressin ligands and receptors that highlight their common origin and clarify the evolutionary background of the crosstalk between them. Second, we conducted a comprehensive review of the increasing evidence for the role of both neuropeptides in regulating social behaviors. Third, we reviewed the growing evidence on the associations between the oxytocin/vasopressin systems and ASD, which includes oxytocin and vasopressin dysfunction in animal models of autism and in human patients, and the impact of treatments targeting the oxytocin or the vasopressin systems in children and in adults. Here, we highlight the potential of targeting the oxytocin/vasopressin systems to improve social deficits observed in ASD and the need for further investigations on how to transfer these research innovations into clinical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.